Ultralow Dose PET Imaging of 18F-FDG Uptake

Launched by AKIVA MINTZ · Apr 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new imaging technique called ultralow dose PET imaging to help detect and monitor cancer. The main goal is to see if they can lower the amount of radiation patients receive during scans by optimizing the timing and technology used. Participants in the study will receive a small injection of a radioactive substance called 18F-FDG, which helps highlight areas of interest during the imaging process. They will be scanned with a special, high-sensitivity PET scanner for up to three hours.

To participate in this trial, you need to be at least 18 years old and able to give consent to join the study. Women who can become pregnant will need to have a negative pregnancy test and must not be pregnant or breastfeeding. People with certain health conditions, like severe claustrophobia or those who have had too much radiation exposure in the past, may not be eligible. This study is not yet recruiting participants, but if you're interested, it could be a chance to help improve cancer detection methods while being closely monitored for safety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥18 years.
• • 2. Ability to provide informed consent and comply with study procedures.
• 3. For female participants:
• • Must not be pregnant or breastfeeding.
• • Negative pregnancy test required for women of childbearing potential.
• Exclusion Criteria:
• • 1. Participants who have exceeded NRC regulation for annual radiation exposure from prior research-related scans, including this study (50 mSv total).
• • 2. More than four prior enrollments in this study.
• • 3. Participants with severe claustrophobia, chronic pain, or musculoskeletal conditions that prevent completion of the PET scan
• • 4. Medication \& Prior Treatment Exclusions
• • 5. Pregnant or breastfeeding individuals (negative pregnancy test required)
• • 6. Inability to provide informed consent
• • 7. Any condition that, in the investigator's judgment, may compromise participant safety or study integrity.